Novo Nordisk, A Leading Global Healthcare Company, Announced That The Us Food And Drug Administration (Fda) Has Approved A 2.0 Mg Dose Of Ozempic (Once-Weekly Semaglutide Subcutaneous Injection), A Glucagon-Like Peptide-1 (Glp-1) Analogue For The Treatment Of Adults With Type 2 Diabetes. Ozempic Is Now Approved In The Us At 0.5 Mg,1.0 Mg And 2.0 Mg Doses For The Treatment Of Type 2 Diabetes In Adults. Further, Ozempic Is Indicated To Reduce The Risk Of Major Cardiovascular Events Such As Heart Attack, Stroke Or Death In Adults With Type 2 Diabetes And Known Heart Disease.The Fda Approval Is Based On The Results From The Sustain Forte Trial. In The Trial, People Treated With Semaglutide 2.0 Mg Achieved A Statistically Significant And Superior Reduction In Hba1C At Week 40 Compared To Semaglutide 1.0 Mg. In The Trial, Both Doses Of Semaglutide Appeared To Have A Safe And Well-Tolerated Profile. The Most Common Adverse Events Were Gastrointestinal. Compared To Semaglutide 1.0 Mg, The Gastrointestinal Adverse Events Were Similar For Semaglutide 2.0 Mg.
